Khalili Mandana, Behm Brian W
University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, NH-3D, San Francisco, CA 94110, USA.
Microbes Infect. 2002 Oct;4(12):1247-51. doi: 10.1016/s1286-4579(02)01652-0.
Hepatitis C virus (HCV) co-infection is common among HIV-infected individuals and can lead to increased morbidity and mortality in this population. HIV adversely impacts the natural history of HCV disease with higher rates of liver disease progression but the effect of HCV on the natural history of HIV is disputed. Additionally, presence of HCV may decrease tolerability of highly active antiretroviral regimens for HIV treatment due to a potential increase in hepatotoxicity. Currently there is limited information available regarding HCV therapy in the setting of HIV co-infection but the HCV virologic response to interferon regimens appears to be similar to those individuals with HCV infection alone. However, additional information is required to assess the efficacy and safety of HCV therapy including possible interaction of HCV and HIV anti-viral medications in these co-infected individuals.
丙型肝炎病毒(HCV)合并感染在HIV感染者中很常见,可导致该人群发病率和死亡率增加。HIV对HCV疾病的自然病程产生不利影响,肝病进展率更高,但HCV对HIV自然病程的影响存在争议。此外,由于肝毒性可能增加,HCV的存在可能会降低用于HIV治疗的高效抗逆转录病毒疗法的耐受性。目前,关于HIV合并感染情况下HCV治疗的可用信息有限,但HCV对干扰素方案的病毒学反应似乎与单纯HCV感染的个体相似。然而,需要更多信息来评估HCV治疗的疗效和安全性,包括这些合并感染个体中HCV和HIV抗病毒药物可能的相互作用。